(Q37885276)

24 August 2017

1 reference

title

Somatic variation and cancer: therapies lost in the mix. (English)

1 reference

24 August 2017

1

Andrew V Biankin

1 reference

24 August 2017

Thomas J Hudson

2

1 reference

24 August 2017

publication date

5 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

130

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

79-91

1 reference

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Biomarker studies: a call for a comprehensive biomarker study registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Phase III and submission failures: 2007–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Genetic progression and the waiting time to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Advances in the preclinical testing of cancer therapeutic hypotheses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Translating insights from the cancer genome into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Randomized clinical trials with biomarkers: design issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Charting a course for genomic medicine from base pairs to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

The development and clinical use of trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Predictive, personalized, preventive, participatory (P4) cancer medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

International network of cancer genome projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Translating clinical trials into meaningful outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Clinical implications of the cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Profiling critical cancer gene mutations in clinical tumor samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

An accelerated pathway for targeted cancer therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Genomics and the continuum of cancer care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

The emergence of resistance to targeted cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Surgery insight: surgical management of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Adaptive Clinical Trial Design: Has Its Time Come?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

When are "positive" clinical trials in oncology truly positive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Cancer epigenetics reaches mainstream oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

The use of response-adaptive designs in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Personalized medicine in oncology: the future is now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Resistance to BRAF inhibition in melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Functional defects in the fanconi anemia pathway in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Methodological and practical challenges for personalized cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-1010-0

Striving to improve outcomes in oncology: unmet expectations in a complex disease

21 January 2018

1 reference

12 December 2020

Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes

1 reference

12 December 2020

Targeting the missing links for cancer therapy

1 reference

12 December 2020

Regulatory watch: FDA guidance on co-developing investigational drugs

1 reference

12 December 2020

The BATTLE trial: personalizing therapy for lung cancer

1 reference

12 December 2020

Molecular biomarkers to individualise treatment: assessing the evidence

1 reference

12 December 2020

WIN Consortium--challenges and advances

1 reference

12 December 2020

Cancer drugs: remedy required

1 reference

12 December 2020

Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors?

1 reference

12 December 2020

Trial watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment

1 reference

12 December 2020

Personalized cancer medicine: era of promise and progress

1 reference

12 December 2020

Genomics drugs in clinical trials

1 reference

12 December 2020

Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification

1 reference

12 December 2020

Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial

1 reference

12 December 2020

Revolution in lung cancer: new challenges for the surgical pathologist

1 reference

12 December 2020

Gene and drug matrix for personalized cancer therapy

1 reference

12 December 2020

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

1 reference

12 December 2020

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

1 reference

12 December 2020

A close look at cancer

1 reference

12 December 2020

Drug resistance: challenges to effective therapy

1 reference

12 December 2020

Implications of personalized medicine--perspective from a cancer center

1 reference

12 December 2020

Cancer genomics: from discovery science to personalized medicine

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.

1 reference

12 December 2020

10.1007/S00439-011-1010-0

Identifiers

DOI

1 reference

24 August 2017

1 reference